The House Energy & Commerce (E&C) Health Subcommittee convened a hearing to examine Medicare coverage of innovative drugs, medical devices, and technology, including the National Coverage Determination (NCD) process and coverage with evidence development (CED) requirements, particularly for Alzheimer’s Disease treatments, and the recently proposed Transitional Coverage for Emerging Technologies (TCET) pathway for breakthrough medical devices. Takeaways from the hearing… (Slifer, July 18, 2023) #Coverage Decisions, #Medical Devices, #Prescription Drugs